Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer - Wikidata - awgldk - TriplyDB

Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer

Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer

http://www.wikidata.org/entity/Q34406526

about

Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer Colorectal cancer in Chinese patients: current and emerging treatment options.KRAS mutation testing in metastatic colorectal cancer Can we accurately report PTEN status in advanced colorectal cancer?Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review Wild-Type KRAS and BRAF Could Predict Response to Cetuximab in Chinese Colorectal Cancer Patients Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine.Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer.Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: a meta-analysis.Mutations in KRAS codon 12 predict poor survival in Chinese patients with metastatic colorectal cancer.Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer.Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies.

P2860

Q28077545-D18E916F-0006-4EE5-B1A2-E273DF0CDB4E Q34352595-9103839D-D1D9-4080-A2B3-EE4DD9CB5282 Q34643960-7069AAA5-347F-4309-9ABD-F59960CF5BCD Q35101357-FD02EB0E-3469-45E5-A22C-4AEABDEE67BF Q36085837-C2F1F931-3751-4D63-B4AE-D285A27801F0 Q36337063-9B0445ED-DB2A-45D2-89E6-A491211C12ED Q36551097-D9BDFFFA-B3CA-4840-828D-379F44774A29 Q37899883-4057B4CC-7239-467F-A867-076C1E134A9D Q38222512-C35A3AC2-DDE7-482B-867E-CB545A079BCE Q42187007-981ACEEA-1EAC-4B3B-B779-C82FA48F1EB9 Q49679318-DC0668FB-FCFE-47EB-9689-54A3E6DF1CE5 Q53548338-AF22437B-219F-4AEA-9E21-A8043804082C Q54509870-BEB4BADF-F178-42C9-9244-789A954FC7BC

P2860

Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer

http://www.wikidata.org/entity/Q34406526

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer

@ast

Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer

@en

Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer

@nl

type

label

Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer

@ast

Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer

@en

Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer

@nl

prefLabel

Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer

@ast

Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer

@en

Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer

@nl

P1433

Q34406526-266FB877-7686-44CD-AC31-D3EFAD77D1E3

P1476

Q34406526-B38EF159-8C00-4114-9B4B-5A4F2B2C4B9B

P2093

Q34406526-1318709B-9269-4DBA-B9A1-891C73B51AD3

Q34406526-2CC40F19-1193-451B-83BD-CC1F3CE860F6

Q34406526-5F7066FA-C3BB-40BF-A9DF-8695B2500EEE

Q34406526-722B8A1C-29A6-4335-963C-1A290C244607

Q34406526-8AF0ED12-0BFF-4AA4-8A8B-3194089CAC43

Q34406526-ADFEDDE3-4366-46BA-9A20-E5CDE56F2953

Q34406526-F0487D5A-4FB5-4470-B052-2E2AC4632798

Q34406526-FBBD0A33-F192-43CA-85D7-A192FA4EAC77

P2860

Q34406526-0A7602E3-6770-45FC-9136-D7A838193FB2

Q34406526-1A35C5A1-F348-4C2F-A8C7-E4661A076AD7

Q34406526-1AC5CF09-4555-416C-B9E0-E985A495F12B

Q34406526-34C3FDD9-C9B3-4175-975E-81CACC7DA63C

Q34406526-3C1F1CC2-9CBC-4387-9A98-0739ADB232B6

Q34406526-40308E39-F5B8-4E23-BC76-D8EB90641E98

Q34406526-4B65A4BE-5447-47EF-8CDF-5DD28B08580F

Q34406526-51D637A7-4FD3-4CAC-A44E-77525BF4C560

Q34406526-58EA4548-F771-44EC-8C77-45B8D6642402

Q34406526-628190D0-8E01-4706-AA4A-5F6991B1F5FA

P304

Q34406526-90B6506D-6DA4-4E2B-87F2-E2E7E9BF9218

P31

Q34406526-551ECED2-464B-4765-87EB-5808DDD9825A

P356

Q34406526-0303DD86-4F96-4B4B-94AA-50A65CF3364B

P407

Q34406526-3A36BDAC-2974-4B0E-B51A-7F77C12BF510

P433

Q34406526-319B4DCE-67C4-408E-9993-968020CAF6C0

P478

Q34406526-6E4B215D-E467-4D05-8734-DF111EAC66C5

P577

Q34406526-EA533F25-30D4-4019-971D-C043880924FC

P5875

Q34406526-B5D94E77-990E-4771-A66C-3E4CC9C60E4A

P698

Q34406526-E66ECAB1-5B77-4825-BAE2-AA2139CC9FDA

P921

Q34406526-3B34966F-E218-45FE-91A7-E8572EA8CB73

Q34406526-E3DE1042-734D-4035-8BF4-CF52C6CA48CD

P932

Q34406526-B2C48198-1CCF-489F-9FBF-C9AC4F58A789

P356

WJG.V16.I46.5881

P1433

World Journal of Gastroenterology

P1476

Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer

@en

P2093

Fang-Hua Li

http://www.w3.org/2001/XMLSchema#string

Hui-Yan Luo

http://www.w3.org/2001/XMLSchema#string

Hui-Zhong Zhang

http://www.w3.org/2001/XMLSchema#string

Lin Shen

http://www.w3.org/2001/XMLSchema#string

Miao-Zhen Qiu

http://www.w3.org/2001/XMLSchema#string

Rui-Hua Xu

http://www.w3.org/2001/XMLSchema#string

Yu-Hong Li

http://www.w3.org/2001/XMLSchema#string

Zhuang-Hua Li

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Molecular determinants of cetuximab efficacy.

The EGFR as a target for anticancer therapy--focus on cetuximab.

P304

5881-5888

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V16.I46.5881

http://www.w3.org/2001/XMLSchema#string

P407

P433

46

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270009247

http://www.w3.org/2001/XMLSchema#string

P698

21155011

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3001981

http://www.w3.org/2001/XMLSchema#string